Jan 10, 2023 / 03:30PM GMT
Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
Great. Good morning, everyone. My name is Jess Fye. I'm the large cap biotech analyst at JPMorgan. Welcome back for Day 2 of our very in-person health care conference. A little different format this year than in the past. You're not going to switch rooms for Q&A. So we're going to, after the presentation, just go seamlessly into Q&A. There's 2 ways to ask questions. You can raise your hand and some will bring you a mic. You can also submit questions electronically through our portal. We'll send it to that iPad up there, and I can read them off for the management team.
So with that out of the way, let me pass it over to NovoCure's Executive Chairman, Bill Doyle for the presentation.
William F. Doyle - NovoCure Limited - Executive Chairman
Thank you, Jess. Good morning, everyone. Welcome to the Sunrise session at JPMorgan. I wasn't sure whether they'd actually be anybody in the room or not at 7:30. So I'm pleased to see everyone. I'll be making forward-looking statements.
Novocure Ltd at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers